Panadol Osteo delisting may impact adherence

The delisting of Panadol Osteo from the PBS may have implications for adherence and progression to use of stronger analgesics in patients with osteoarthritis, a study suggests.

Patients with OA who took extended-release paracetamol (665mg) were more likely to take the medication regularly and less likely to progress to opioid-containing analgesics, according to an analysis of PBS data from 2009/2010.